Pharma Mar Signs Licensing, Development And Commercialization Agreement With Merck For Lurbinectedin In Japan
Reuters
03 Apr
April 3 (Reuters) - Pharma Mar SA:: *SIGNS LICENSING, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT WITH MERCK FOR LURBINECTEDIN IN JAPAN *WILL RECEIVE UPFRONT PAYMENT OF 22 MILLION EUROS *ENTITLED TO TIERED DOUBLE DIGIT ROYALTIES ON NET SALES, AND VARIOUS CLINICAL, REGULATORY, AND SALES BASED MILESTONES TOTALLING UP TO AN ADDITIONAL 31 MILLION EUROS *WILL SUPPLY MERCK WITH LURBINECTEDIN FOR CLINICAL AND COMMERCIAL USE IN JAPAN
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.